RxDoctor Payments Data

Teresa Thomas, MD

Internal Medicine · Bronx, NYNPI 1902175854

Payments from drug & device makers

$4,383in general payments, 2019–2025

Across 110 payments — averaging $39.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$1K
  • Merck$373
  • AbbVie$252
  • Novo Nordisk$125
  • Boehringer Ingelheim$120
  • plus $250 from 8 others

What the payments were for

  • Food & beverage$4,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,383 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$71,315
Medicare patients
77
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala38$144,132
JanuviaSitagliptin Phosphate101$72,713
OdefseyEmtricitab/Rilpiviri/Tenof Ala15$54,219
DescovyEmtricitabine/Tenofov Alafenam24$51,402
JardianceEmpagliflozin61$40,773
OzempicSemaglutide29$33,050
EliquisApixaban63$31,694
IsentressRaltegravir Potassium14$27,985
TrulicityDulaglutide29$26,623
CreonLipase/Protease/Amylase15$20,443
XareltoRivaroxaban36$18,993
TivicayDolutegravir Sodium15$18,125
JanumetSitagliptin Phos/Metformin Hcl15$13,843
Albuterol Sulfate HfaAlbuterol Sulfate323$9,646
SantylCollagenase Clostridium Hist.12$9,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,800$195,53562 claims
MerckJanuvia, Isentress, Janumet$373$114,541130 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Pradaxa$120$54,625105 claims
Novo NordiskOzempic$125$33,05029 claims
Lilly USA, LLCTrulicity$53$26,62329 claims
AbbVieCreon, Lumigan$252$24,23329 claims
Viiv Healthcare CompanyTivicay$1,463$18,12515 claims
GSKBreo Ellipta$26$7,04618 claims
AstraZenecaSymbicort$14$2,86114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →